Rnr1 and rnr2, which form heterodimeric tetramers and a unique feature of note is the. A novel ligandbinding pocket on the rnr small subunit rrm2 near. Inhibition of ribonucleotide reductase reduces the availability of the endogenous pool of deoxycytidine and may increase cytarabine arac cytotoxicity. Inhibition of dna synthesis and ribonucleotide reductase activity by chl hct116 cells were pretreated with chl and pulse. Methylhydroxylamine as an efficacious antibacterial agent. Ribonucleotide reductase inhibitor 3ap induces oncogenic. In a future subject, it will be shown that two of these compounds specifically inhibit the m1 subunit of the ribonucleotide reductase enzyme and it will also be shown that 2halogen substituted adenosine derivatives are especially potent inhibitor of rnr. The results of this study will lead to the design of future generations of.
It is therefore an excellent target for cancer chemotherapy. The key role of rr in dna synthesis and cell growth control has made it an important. Funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Ribonucleotide reductase inhibitors and future drug. Citeseerx document details isaac councill, lee giles, pradeep teregowda. There are three classes of rnrs classes i iii, but only class i are present in eukaryotes. Ribonucleotide reductase rnr, containing regulatory hrrm1. So, homology modeling contributes much in the drug discovery. One major advantage of coh29 over other rnr inhibitors in development, such. Coh29 n 43,4dihydroxyphenyl5phenylthiazol2yl3,4dihydroxybenzamide, a novel antimetabolite drug developed at city of hope cancer center, has anticancer activity that stems primarily from the inhibition of human ribonucleotide reductase rnr. This enzyme, in presence of iron and reduced hs groups converts monophosphate and diphosphate ribonucleotides adenosine, guanosine, cytidine into the corresponding deoxyribonucleotides.
Yen y 2006 ribonucleotide reductase inhibitors and future drug design. Structureguided design of anticancer ribonucleotide. Investigating synergy between ribonucleotide reductase inhibitors and cmv antivirals a thesis submitted in partial fulfillment of the requirements for the degree of master of science at virginia commonwealth university. Design and synthesis of potential ribonucleotide reductase. Shao j, zhou b, chu b, yen y 2006 ribonucleotide reductase inhibitors and future drug design. Evaluating the therapeutic potential of a nonnatural. The nucleoside analog gemcitabine, which targets ribonucleotide reductase rr as a diphosphate and dna polymerases as a triphosphate, is the standard firstline treatment in patients with pancreatic cancer. Pdf ribonucleotide reductase rr is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding. Drugs targeting rr are mainly nucleoside in nature. Cyclin fmediated degradation of ribonucleotide reductase. Ribonucleotide reductase rr is the enzyme that catalyses the ratelimiting step in dna synthesis, the production of deoxynucleotides. Ribonucleotide reductase rr is a therapeutic target for dna replicationdependent diseases such as cancer.
Discovery of antimicrobial ribonucleotide reductase. Future work will involve the study of the structureactivity relationship. Modulation of the ribonucleotide reductaseantimetabolite. The emergence of multidrugresistant bacteria has encouraged vigorous efforts to develop antimicrobial agents with new mechanisms of action. Ribonucleotide reductase rnr is a key enzyme in dna replication that acts by converting ribonucleotides into the corresponding deoxyribonucleotides, which are the building blocks of dna replication and repair. Human ribonucleotide reductase hrr is a ubiquitous multisubunit enzyme that is crucial for cell division and dna repair14. Rr activity is markedly elevated in tumour tissue and is crucial for cell division. Rnr is a wellestablished target for the antiproliferative drugs gemzar and hydrea, for antisense therapy, and in combination chemotherapies. In this study, a lcmsbased method was carried out to investigate the metabolic alteration of ribonucleotide and deoxyribonucleotide in human promyelocytic leukemia cells hl60 after treatment. Structureguided design of anticancer ribonucleotide reductase inhibitors article pdf available in journal of enzyme inhibition and medicinal chemistry 341. Phase i study of gti2040, an antisense to ribonucleotide.
Provided herein are novel compounds that inhibit ribonucleotide reductase rr by binding to rrm2 and interfering with the activity of the rrm1rrm2 holoenzyme. Despite the apparent clinical benefits of highdose cytarabine arac over lower dose arac in acute myeloid leukemia aml therapy, the mechanism behind highdose arac therapy remains uncertain. Gemcitabine is a billiondollar drug used as a front line treatment of. Gene expression level was quantified by a software package called rsem. Evaluating the therapeutic potential of a nonnatural nucleotide that inhibits human ribonucleotide reductase. Ribonucleotide reductase is composed of two subunits. This antineoplastic or immunomodulatory drug article is a stub. Ribonucleotide reductase rnr catalyzes reduction of the four different. City of hope national medical center, 1500 east duarte road, duarte, ca 91010, usa. We performed a phase i dose escalation trial of arac combined with gti2040, a 20mer antisense oligonucleotide. Identification of nonnucleoside human ribonucleotide reductase.
Ohgroup of a ribonucleotide with a hydrogen by a mechanism involving protein radicals. Cellular assay for rnr inhibitors this assay has been specially tailored to validate ribonucleotide reductase rnr inhibition by a given compound in cultured cells. It catalyzes this formation by removing the 2hydroxyl group of the ribose ring of nucleoside diphosphates. Here, a potent small interfering rna sirna duplex against the m2 subunit of rr rrm2 is developed and shown to reduce the growth potential of cancer cells both in vitro and in vivo. This chapter presents the progress in the design and discovery of hydroxamic acids acting as ribonucleotide reductase rr inhibitors. Qsar and pharmacophore analysis of thiosemicarbazone. Design and synthesis of potential ribonucleotide reductase enzyme rnr inhibitors as antileukemic andor antiviral 2. In the absence of chl treatment, most of the brdu labeling 96% was associated with the s. The development of rr inhibitors has necessarily advanced along with our. The enzyme has thus an attractive target for chemotherapies that fight proliferationbased diseases. Three classes of rnrs employ different mechanisms for the generation of the protein radical. Ribonucleotide reductase rr is a ubiquitous multisubunit enzyme that.
The search for anticancer drugs continues to be greatly pursued. Ribonucleotide reductases rnrs transform rna building blocks to dna building blocks by catalyzing the substitution of the 2. The expression of ribonucleotide reductase m2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. Deoxyribonucleotides in turn are used in the synthesis of dna. Ribonucleotide reductase inhibitors and fut ure drug design current cancer drug target s, 2006, vol. The novel ribonucleotide reductase inhibitor coh29 inhibits dna repair in vitro. Ribonucleotide reductase inhibition assays and mechanism. Ribonucleotide reductase rr is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for dna replication and repair. Ribonucleotide reductase inhibitors and future drug design volume. Cellbased assay ribonucleotide reductase inhibition. Development of ribonucleotide reductase inhibitors.
However, its cytotoxicity to normal dividing tissues leads to unwanted side effects. This key enzyme in deoxyribonucleotide biosynthesis is the target of established clinical agents such as hydroxyurea and gemcitabine. Ribonucleotide reductase inhibitors are a family of anticancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides building. Understanding the mechanism for ribonucleotide reductase. To test this hypothesis, we treated breast cancer mdamb231 cells with tamoxifen tmx, which induces autophagy through an estrogen receptorindependent pathway. Ribonucleotide reductase assay was performed as previously described, with slight modification. Ribonucleotide reductase, cancer, inhibitor, pancreatic. The key role of rr in dna synthesis and cell growth control has made it an important target for anticancer therapy. The cincinnati library consisting of 350,000 compounds was screened in silico using the schrodinger software. Ribonucleotide reductase rnr is an attractive target for anticancer agents. Modulation of the ribonucleotide reductaseantimetabolite drug interaction in cancer cell lines. Loss of the transcription factor p53 implies mrna losses of target genes such as the p53r2 subunit of human ribonucleotide reductase rnr. Rare side effects include nausea, rashes, mouth ulcers, and hand or leg ulcers. The expression of ribonucleotide reductase m2 in the.
The p53 gene is frequently inactivated in human cancers. Sorafenib inhibits ribonucleotide reductase regulatory subunit m2 rrm2 in hepatocellular carcinoma cells. Potent competitive inhibition of human ribonucleotide. Here we have isolated a p53inducible gene, p53r2, by using differential display to examine messenger rnas in a cancerderived human cell.
Ribonucleotide reductase, structure and function, inhibitors, classification, mechanism of action, clinical trial and application, drug discovery. A smallmolecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance bingsen zhou, leila su, shuya hu, weidong hu, m. A smallmolecule blocking ribonucleotide reductase holoenzyme. Dna replication stress is an inefficient dna synthesis process that leads replication forks to progress slowly or stall.
These groups are showed to be active as ribonucleotide reductase inhibitors and their incorporation results in a bioconjugate. A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, nonsmall cell lung. Hydroxyurea, a ribonucleotide reductase inhibitor, is a welltolerated oral cytotoxic agent that can control blood cell counts rapidly in most patients with cml. Hydroxyurea, also called hydroxycarbamide, nh2conhoh, inhibit ribonucleotidediphosphate reductase.
Hydroxamates as ribonucleotide reductase inhibitors. Surprisingly, few novel drugs that target rnr have emerged, partly. After incubation of cultured cells with the inhibitor, this high performance liquid chromatography analysis of nucleotides consists in. Ribonucleotide reductase rnr catalyzes reduction of the four different ribonucleotides to their corresponding deoxyribonucleotides and is the ratelimiting enzyme in dna synthesis. Ribonucleotide reductase rr is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for dna. Rr catalyses the ratedetermining step of dntp synthesis by removing the 2. The novel ribonucleotide reductase inhibitor coh29. Next, we further characterized the mechanism of inhibition using. Potent competitive inhibition of human ribonucleotide reductase by a. Sorafenib inhibits ribonucleotide reductase regulatory. Ribonucleotide reductase rnr, also known as ribonucleotide diphosphate reductase rndp, is an enzyme that catalyzes the formation of deoxyribonucleotides from ribonucleotides. Discovery of antimicrobial ribonucleotide reductase inhibitors by.
Therapeutics program dtp nci diversity set freeforpublic access. Two main factors that cause replication stress are alterations in pools of deoxyribonucleotide dntp precursors required for dna synthesis and changes in the activity of proteins required for synthesis of dntps. We hypothesized that other genes in the dntp supply system would compensate for such p53r2 losses and looked for this in our own data and in data of the gene expression omnibus geo. Nheterocyclic carboxaldehyde thiosemicarbazones derivatives exhibit anticancer activity by inhibiting ribonucleotide reductase rnr enzyme was considered for the present computational study. Homology modeling is used in determining 3d structures of proteins, and it has many applications in the drug discovery process. Potent sirna inhibitors of ribonucleotide reductase. The novel ribonucleotide reductase inhibitor coh29 inhibits dna. Using affinity purifications and mass spectrometry, we identified rrm2 the ribonucleotide reductase family member 2 as an interactor of the fbox protein cyclin f.
Ribonucleotide reductase rnr catalyzes the conversion of ribonucleotides to deoxyribonucleotides dntps, which are necessary for both replicative and repair dna synthesis. While some researchers have focused on rr inhibitors as chemotherapeutic agents, particularly in hematologic malignancies, some of the most promising data has been generated in the field of radiosensitization. Recent structural studies of members from each class have led to a deeper understanding. Detailed annotation on the structure, function, physiology, pharmacology and clinical relevance of drug targets. Ribonucleotide reductase inhibitor 3ap induces oncogenic virus infected cell death and represses tumor growth. Pdf ribonucleotide reductase inhibitors and future drug design. We performed a phase i dose escalation trial of arac combined with gti2040, a 20mer antisense oligonucleotide shown in preclinical studies to decrease levels of the r2 subunit of ribonucleotide reductase, to determine the maximum. Meng lou, qian liu, guoping ren, jiling zeng, xueping xiang, yongfeng ding, qinghui lin, tingting zhong, xia liu, lijun zhu, hongyan qi, jing shen, haoran li, jimin shao. Ribonucleotide reductase rnr is the key enzyme in the biosynthesis of deoxyribonucleotides. Ribonucleotide reductase rr, the rate limiting enzyme in the synthesis and repair of dna, has been studied as a target for inhibition in the treatment of cancer for many years. Furthermore, in the near future, integration of homology modeling with other computer. Structureguided design of anticancer ribonucleotide reductase. Ribonucleotide reductase inhibitors and future drug design.
1040 1362 614 308 1578 994 112 1568 1531 434 1640 1373 1383 208 197 1643 777 618 229 779 1240 1367 203 679 1314 678 1080 730 1223 308 784 1380 1564 631 194 144 163 805 1281 831